Mr. Macaluso is the Chief Executive Officer, founder and Director of Ampio Pharmaceuticals, Inc. and DMI Life Sciences, Inc. Mr. Macaluso has extensive entrepreneur experience over the past 20 years. He was the founder and principal of International Printing and Publishing managing all phases of its domestic and international commercial printing operations from 1989 until 1997, the owner of Page International Communications, a manufacturing business, from 1998 until 2001, and in 2001 formed Isolagen, Inc, serving as a Director and as President and Chief Executive Officer. Mr. Macaluso is a graduate of Canisius College.
David Bar-Or, M.D., Chief Scientific Officer and Director
Dr. Bar-Or is Chief Scientific Officer and Director of Ampio Pharmaceuticals, Inc. and held the same positions for DMI Life Sciences, Inc. He founded DMI BioSciences, Inc. in 1990, serving as Chief Scientific Officer and Director. Dr. Bar-Or has over thirty-five years experience in biochemical/molecular biology research, is a Fellow of the American College of Emergency Physicians, and was in clinical practice for twenty three years, including five years as director of emergency medicine at an accredited trauma center. He is presently Director of Trauma Research for two level one trauma Centers: Swedish Medical Center and St. Anthony Central Hospital. Dr. Bar-Or received his M.D. from Hebrew University Medical School, Jerusalem, Israel, completed his residency in Emergency Medicine at Denver Health Medical Center and was the first to complete a fellowship in Emergency Medicine research at Denver Health Medical Center, a program recognized nationally as a leader in emergency medicine. Dr. Bar-Or has received numerous awards for outstanding clinical and scientific research, published over 85 scientific articles, holds over 52 issued US and international patents, and has filed over 119 additional US and international patent applications.
Philip Coelho, Director
Mr. Coelho, is currently CEO and President of Synergenesis, Inc., a firm inventing and commercializing products that harness stem and progenitor cells derived from the patient’s own body to treat human disease. He has been in the senior management of high technology consumer electronic or medical device companies for over 30 years. Prior to founding Synergenesis, Mr. Coelho has served as President and CEO of PHC Medical, Inc., Chairman and Chief Executive Officer of ThermoGenesis Corp., President of Castleton Inc. and President of ESS Inc. He currently serves as a member of the Board of Directors of Catalyst Pharmaceuticals Partners, Inc. and Mediware Information Systems, Inc. Mr. Coelho received a B.S. degree in thermodynamic and mechanical engineering from the University of California, Davis and has been awarded more than 30 U.S. patents in the areas of cell cryopreservation, cryogenic robotics, cell selection, blood protein harvesting and surgical hemostasis.
Richard B. Giles, Director
Richard B. Giles joined the Ampio Board of Directors in August 2010. He is the Chair of the Audit committee, and a Member of the Compensation Committee and the Nominating and Governance Committee. He currently serves as the Chief Financial Officer of Ludvik Electric Co., an electrical contractor headquartered in Lakewood, Colorado, a position he has held since 1985. Ludvik Electric is a private electrical contractor with 2009 revenues of over $100 million that has completed electrical contracting projects throughout the Western United States, Hawaii, and South Africa. As CFO and Treasurer of Ludvik Electric, Mr. Giles oversees accounting, risk management, financial planning and analysis, financial reporting, regulatory compliance, and tax-related accounting functions. He serves also as the trustee of Ludvik Electric Co.’s 401(k) plan. Prior to joining Ludvik Electric, Mr. Giles was for three years an audit partner with Higgins Meritt & Company, then a Denver, Colorado CPA firm, and during the preceding nine years he was an audit manager and a member of the audit staff of Price Waterhouse, one of the legacy firms which now comprises PricewaterhouseCoopers. While with Price Waterhouse, Mr. Giles participated in a number of public company audits, including one for a leading computer manufacturer. Mr. Giles received a B.S. degree in accounting from the University of Northern Colorado and is a Certified Public Accountant. He is also a member of the American Institute of Certified Public Accountants and the Construction Financial Management Association.
David R. Stevens, Ph.D., Director
Dr. Stevens is currently Executive Chairman of Cedus, Inc., a private development stage biopharmaceutical company, and also a board member of Poniard Pharmaceuticals, Inc., and Aqua Bounty Technologies, Inc., both public life science development stage companies, as well as Micro-Imaging Solutions, LLC, a private medical device company. He was an advisor to Bay City Capital from 1999-2006. Dr. Stevens was previously President and CEO of Deprenyl Animal Health, Inc., a public veterinary pharmaceutical company, from 1990 to 1998, and Vice President, Research and Development, of Agrion Corp., a private biotechnology company, from 1986 to 1988. He began his career in pharmaceutical research and development at the former Upjohn Company, where he contributed to the preclinical evaluation of Xanax and Halcion. Dr. Stevens received BS and DVM degrees from Washington State University, and a Ph.D. in Comparative Pathology from the University of California, Davis. He is a Diplomate of the American College of Veterinary Pathologists. Dr. Stevens has worked in the pharmaceutical and biotechnology industries since 1978. He brings to the board a diversity of management, operational, and product development experience, including as the former chief executive officer of a public veterinary pharmaceutical company and as an active participant in the medical device industry.
Learn More About:
Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.
A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness
A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis
|AMPE Stock Quote - delayed|
05/13/2013 | Press Release
04/25/2013 | Press Release
04/02/2013 | Press Release